gefitinib has been researched along with Mesothelioma in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ikeda, S; Suzuki, K; Takabe, K | 1 |
| Bajetto, A; Barbieri, F; Corte, G; Favoni, RE; Florio, T; Gatti, M; Gaudino, G; Lo Casto, M; Mutti, L; Paleari, L; Pattarozzi, A; Porcile, C | 1 |
| Baldi, A; Canino, C; Cardillo, I; Galati, R; Sacchi, A; Stoppoloni, D; Verdina, A | 1 |
| Bellini, P; Favoni, RE; Harvey, BJ; Manente, AG; Moro, L; Mutti, L; Pinton, G; Thomas, W | 1 |
| Bueno, R; Corson, JM; Fletcher, JA; Flynn, DL; Hubert, C; Ou, WB; Sugarbaker, DJ | 1 |
| Dhalluin, X; Scherpereel, A | 1 |
| Jänne, PA; Johnson, BE; Salgia, R; Taffaro, ML | 1 |
| Govindan, R; Green, MR; Herndon, JE; Kindler, HL; Kratzke, RA; Niehans, GA; Vollmer, R; Watson, D | 1 |
| Cortese, JF; Eliason, JF; Everson, RB; Gowda, AL; Pass, HI; Wali, A | 1 |
| Goto, H; Hanibuchi, M; Ikuta, K; Kakiuchi, S; Nakataki, E; Nishioka, Y; Ogino, H; Ryan, A; Sone, S; Yamada, T; Yano, S | 1 |
1 review(s) available for gefitinib and Mesothelioma
| Article | Year |
|---|---|
Chemotherapy and radiotherapy for mesothelioma.
Topics: Antineoplastic Agents; Asbestos; Combined Modality Therapy; Gefitinib; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Mesothelioma; Pleural Neoplasms; Quinazolines; Ribonucleases; Thalidomide | 2011 |
1 trial(s) available for gefitinib and Mesothelioma
| Article | Year |
|---|---|
Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Male; Mesothelioma; Middle Aged; Peritoneal Neoplasms; Pleural Neoplasms; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2005 |
8 other study(ies) available for gefitinib and Mesothelioma
| Article | Year |
|---|---|
[Epidermal growth factor receptor aberrations in malignant mesotheliomas].
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mesothelioma; Quinazolines | 2009 |
Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Cross-Linking Reagents; ErbB Receptors; Fluorescent Antibody Technique; Gefitinib; Humans; Mesothelioma; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Pleural Neoplasms; Protein Multimerization; Quinazolines; Tumor Cells, Cultured | 2010 |
Synergistic effect of gefitinib and rofecoxib in mesothelioma cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclooxygenase 2; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lactones; Mesothelioma; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sulfones | 2010 |
Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib.
Topics: Blotting, Western; Caveolin 1; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Estrogen Receptor beta; Gefitinib; Humans; Immunoprecipitation; Mesothelioma; Microscopy, Confocal; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Pleural Neoplasms; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference | 2010 |
Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.
Topics: Antineoplastic Agents; Apoptosis; Axl Receptor Tyrosine Kinase; Benzoquinones; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Interactions; Enzyme Activation; ErbB Receptors; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Indoles; Lactams, Macrocyclic; Mesothelioma; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Sulfones | 2011 |
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mesothelioma; Phosphorylation; Pleural Neoplasms; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2002 |
Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma.
Topics: Adenocarcinoma; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Mesothelioma; Point Mutation; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Base Sequence; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Rearrangement; Humans; Male; Mesothelioma; Mice; Mice, SCID; Molecular Sequence Data; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Pleural Neoplasms; Proto-Oncogene Proteins c-ret; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2008 |